AbbVie Inc. Sets New 1-Year High at $48.95 (ABBV)
AbbVie (NASDAQ:ABBV) set a new 52-week high during trading on Friday, American Banking News reports. The stock traded as high as $48.95 and last traded at $48.40, with a volume of 6,415,467 shares. The stock had previously closed at $48.17.
A number of analysts have recently weighed in on ABBV shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of AbbVie in a research note to investors on Friday, October 11th. They now have a $55.00 price target on the stock, up previously from $54.00. Separately, analysts at Credit Suisse initiated coverage on shares of AbbVie in a research note to investors on Tuesday, October 8th. They set an “outperform” rating on the stock. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $48.40.
AbbVie has a 1-year low of $33.33 and a 1-year high of $48.42. The stock has a 50-day moving average of $45.27 and a 200-day moving average of $44.19. The company has a market cap of $76.624 billion and a price-to-earnings ratio of 14.80.
AbbVie (NASDAQ:ABBV) last released its earnings data on Friday, July 26th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.13. The company had revenue of $4.69 billion for the quarter, compared to the consensus estimate of $4.54 billion. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Analysts expect that AbbVie will post $3.13 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, November 15th. Stockholders of record on Tuesday, October 15th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.32%. The ex-dividend date of this dividend is Thursday, October 10th.
AbbVie Inc (NASDAQ:ABBV) is a research-based pharmaceuticals company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.